Diagnosing biliary strictures — narrowings in the bile ducts — as cancerous or benign is notoriously tricky. Standard tools like ERCP-guided biopsies and the blood marker CA19-9 often fall short, especially in early-stage disease. Now, a study published in eGastroenterology suggests that bile collected during routine ERCP could be repurposed as a genomic resource to detect pancreatobiliary tumors earlier and more accurately.

Researchers analyzed 95 patients with radiologically suspicious biliary strictures using ultra-low-pass whole-genome sequencing (ULP-WGS) of bile cell-free DNA — requiring just 2 nanograms of DNA. Among initially indeterminate strictures later confirmed as malignant, the test achieved 51% sensitivity and an impressive 96% specificity. In 23 patients, tumor DNA was detected a median of 38 days before conventional diagnosis, with some cases flagged more than 100 days earlier.

Key Takeaways:

• ULP-WGS detected tumor DNA in 73% of confirmed malignancies (82% of cholangiocarcinomas, 56% of pancreatic ductal adenocarcinomas)
• A 50-region CNA classifier distinguished cholangiocarcinoma from pancreatic cancer with ~85–86% accuracy
• Patients who were both tumor-fraction positive and had mutations in ≥3 genes had a median survival of 5.1 months vs. 13.7 months for others
• Sequencing costs are estimated to be 130–215× lower than conventional whole-genome sequencing

Why it matters: This approach won't replace tissue biopsy, but it could be a valuable complementary tool when the first ERCP is inconclusive — potentially accelerating diagnosis, reducing repeated procedures, and giving clinicians a head start on treatment planning for some of the hardest-to-catch cancers.